首页 › 基金 › Mass General Brigham, Inc › MAZE
Mass General Brigham, Inc 对 MAZE 的持仓历史
MAZE THERAPEUTICS INC · 医疗保健
Mass General Brigham, Inc 在 Q3 2026 的 13F 申报中披露持有 MAZE(MAZE THERAPEUTICS INC)249,636 股,市值约 US$6.8M,约占其申报组合的 1.57%,在其申报持仓中市值排名第 5 位。 Mass General Brigham, Inc 最近 4 个申报季度中有 4 个季度披露了 MAZE 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-03 · 来源: SEC EDGAR Form 13F-HR
Mass General Brigham, Inc 对 MAZE 的持仓演变
Mass General Brigham, Inc 于 Q4 2025 首次披露 MAZE 持仓:239,994 股(约 US$9.9M)。 在 4 次申报中,Mass General Brigham, Inc 1 次增持、0 次减持、2 次保持不变。 最近一期申报(Q3 2026)显示持股 249,636 股、市值约 US$6.8M,环比增持 9,642 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 239.99K | $9.94M | 新进 |
| Q1 2026 | 239.99K | $7.16M | 持有 |
| Q2 2026 | 239.99K | $7.16M | 持有 |
| Q3 2026 | 249.64K | $6.79M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 MAZE 与 13F 数据
MAZE(MAZE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 74 只申报持有 MAZE,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 MAZE 的基金
- Frazier Life Sciences Management, L.P. 5.03M 股 · $150.18M · Q2 2026
- TRV GP IV, LLC 4.47M 股 · $133.50M · Q2 2026
- ARCH Venture Management, LLC 4.12M 股 · $122.98M · Q2 2026
- Deep Track Capital, LP 3.73M 股 · $111.38M · Q2 2026
- Logos Global Management LP 1.94M 股 · $57.74M · Q2 2026
- a16z Capital Management, L.L.C. 1.70M 股 · $50.79M · Q2 2026
- Venrock Adviser, LLC 1.60M 股 · $47.80M · Q2 2026
- Alphabet Inc. 1.39M 股 · $41.44M · Q2 2026
- BRAIDWELL LP 1.14M 股 · $34.02M · Q2 2026
- 法拉龙资本管理 1.11M 股 · $33.06M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.11M 股 · $33.06M · Q2 2026
- General Catalyst Group Management, LLC 1.04M 股 · $30.91M · Q2 2026
更多关于 Mass General Brigham, Inc
常见问题
How long has Mass General Brigham, Inc held MAZE?
Mass General Brigham, Inc has disclosed MAZE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Mass General Brigham, Inc's current position in MAZE?
As of Q3 2026, Mass General Brigham, Inc holds 249.64K shares of MAZE (MAZE THERAPEUTICS INC), valued at $6.79M, representing 1.57% of its reported portfolio and ranking #5.
Has Mass General Brigham, Inc been buying or selling MAZE?
In the latest 13F filing (Q3 2026), Mass General Brigham, Inc increased its position in MAZE.
Which other funds hold MAZE?
Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.